Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Wim van Boxtel"'
Autor:
Stefanie D. Krens, Wim van Boxtel, Carla M.L. van Herpen, Sasja F. Mulder, Frank G A Jansman, Maike J. M. Uijen, Ingrid M.E. Desar, Nielka P. van Erp
Publikováno v:
International Journal of Cancer, 150, 308-316
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
Contains fulltext : 249093.pdf (Publisher’s version ) (Open Access) Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c98ce1a967df31e36b3fab93fbb978
https://doi.org/10.1002/ijc.33797
https://doi.org/10.1002/ijc.33797
Autor:
Wim van Boxtel, Maike J.M. Uijen, Stefanie D. Krens, Tim Dijkema, Stefan M. Willems, Marianne A. Jonker, Sjoert A.H. Pegge, Adriana C.H. van Engen-van Grunsven, Carla M.L. van Herpen
Publikováno v:
European Journal of Cancer, 161, 128-137
European Journal of Cancer, 161, 128-137. ELSEVIER SCI LTD
European Journal of Cancer, 161, pp. 128-137
European Journal of Cancer, 161, 128-137. ELSEVIER SCI LTD
European Journal of Cancer, 161, pp. 128-137
Contains fulltext : 249569.pdf (Publisher’s version ) (Open Access) AIM: Because the tyrosine kinases c-MET and vascular endothelial growth factor receptors (VEGFR) are often overexpressed in salivary gland cancer (SGC), this study evaluated the ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34fd01145c0396da5db37aed05ff9ae7
https://doi.org/10.1016/j.ejca.2021.10.033
https://doi.org/10.1016/j.ejca.2021.10.033
Autor:
Martin Gotthardt, Gerald W. Verhaegh, Ilse van Engen-van Grunsven, James Nagarajah, Marianne A. Jonker, Susanne Lütje, Wim van Boxtel, Jack A. Schalken, Carla M.L. van Herpen
Publikováno v:
Theranostics
Theranostics, 10, 2273-2283
Theranostics, 10, 5, pp. 2273-2283
Theranostics, 10, 2273-2283
Theranostics, 10, 5, pp. 2273-2283
Rationale: Treatment options for recurrent and/or metastatic (R/M) adenoid cystic carcinoma (ACC) and salivary duct carcinoma (SDC), major subtypes of salivary gland cancer, are limited. Both tumors often show overexpression of prostate-specific memb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b72d498d6a6a2b2e4418675cb1ad8d26
https://doi.org/10.7150/thno.38501
https://doi.org/10.7150/thno.38501
Autor:
Gerben Lassche, Wim van Boxtel, Tilly W. Aalders, Onno van Hooij, Adriana C.H. van Engen - van Grunsven, Gerald W. Verhaegh, Carla M.L. van Herpen, Jack A. Schalken
Publikováno v:
Oral Oncology, 135
Contains fulltext : 287577.pdf (Publisher’s version ) (Open Access) OBJECTIVE: Three-dimensional organoid cell cultures have been established for a variety of human cancers. For most rare cancers, including salivary gland cancer (SGC), these models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb1a1531c669c3e2dfe91f3c1017d91
Publikováno v:
Clinical Nuclear Medicine, 45, 9, pp. 716-718
Clinical Nuclear Medicine
Clinical Nuclear Medicine, 45, 716-718
Clinical Nuclear Medicine
Clinical Nuclear Medicine, 45, 716-718
Contains fulltext : 225059.pdf (Publisher’s version ) (Open Access) Adenoid cystic carcinoma is a rare cancer that arises from secretory glands. Metastases are mainly seen in the lungs and bones. Cardiac metastases are extremely rare; only 1 case h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8bae4a344473a04e6c6261a845f0622
https://doi.org/10.1097/rlu.0000000000003204
https://doi.org/10.1097/rlu.0000000000003204
Autor:
Ilse van Engen-van Grunsven, Gerald W. Verhaegh, Stefan M. Willems, Wim van Boxtel, Maike J. M. Uijen, Jack A. Schalken, Marianne A. Jonker, Carla M.L. van Herpen
Publikováno v:
Oral Oncology, 110:105018. ELSEVIER SCIENCE BV
Oral Oncology, 110
Oral Oncology, 110
Objectives: Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer. Androgen receptor (AR) (96%) and HER2 (29-46%) expression, and a high propensity for regional lymph node metastases are hallmarks of the disease. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f7e194f1aac66bf14327bdeb8026f5
https://pubmed.ncbi.nlm.nih.gov/33039794
https://pubmed.ncbi.nlm.nih.gov/33039794
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
Autor:
Leonie I. Kroeze, Anja van de Stolpe, Gerald W. Verhaegh, Hans Van Zon, Yara Hendriksen, M.J.L. Ligtenberg, Wim van Boxtel, Dianne Arnoldina Margaretha Wilhelmina Van Strijp, Ilse A. van Engen ‐ van Grunsven, Jack A. Schalken, Carla M.L. van Herpen, Diederick Keizer
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 146, 11, pp. 3196-3206
International Journal of Cancer, 146, 3196-3206
International Journal of Cancer, 146, 11, pp. 3196-3206
International Journal of Cancer, 146, 3196-3206
Androgen deprivation therapy (ADT) is first‐line palliative treatment in androgen receptor‐positive (AR+) salivary duct carcinoma (SDC), and response rates are 17.6–50.0%. We investigated potential primary ADT resistance mechanisms for their pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0555fc865a282e0a8cdba87f1eda44f0
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/220464
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/220464
Autor:
Ann Hoeben, Simone E. J. Eerenstein, Robert J.J. van Es, Max J. H. Witjes, Marianne A. Jonker, Uta Flucke, Lilly-Ann van der Velden, Stefan M. Willems, Robert J. Baatenburg de Jong, Eline Boon, Miranda Bel, Michiel W. M. van den Brekel, Sjoukje F. Oosting, Wim van Boxtel, Winette T. A. van der Graaf, Elisabeth Bloemena, Carla M.L. van Herpen, Laura A. Smit
Publikováno v:
International Journal of Cancer. 143:758-766
Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis and a need for better prognostication and novel treatments. The aim of this national cohort study was to investigate clinical outcome, prognostic factors, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fbc3ea457dd20e44810db44f3341890
https://doi.org/10.1002/ijc.31353
https://doi.org/10.1002/ijc.31353
Autor:
Sasja F. Mulder, Maike J. M. Uijen, Nielka P. van Erp, Stefanie D. Krens, Frank G A Jansman, Carla M.L. van Herpen, Ingrid M.E. Desar, Wim van Boxtel
Publikováno v:
Cancer Research. 81:1363-1363
Background Cabozantinib is approved for treatment of renal cell cancer (RCC) in a starting dose of 60 mg. However, in the registration studies dose reductions were needed in 46-62% of patients due to toxicity. Improved clinical efficacy of cabozantin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a66bfd8998a4689230c96c13354c831b
https://doi.org/10.1158/1538-7445.am2021-1363
https://doi.org/10.1158/1538-7445.am2021-1363
Autor:
Carla M.L. van Herpen, Eline Boon, Uta Flucke, Willem L. J. Weijs, Wim van Boxtel, Frank J. A. van den Hoogen
Publikováno v:
Oral Oncology, 72, pp. 198-200
Oral Oncology, 72, 198-200
Oral Oncology, 72, 198-200
Contains fulltext : 177558.pdf (Publisher’s version ) (Open Access)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a588080800be9d4070ec93be28ff99fc
https://doi.org/10.1016/j.oraloncology.2017.06.023
https://doi.org/10.1016/j.oraloncology.2017.06.023